1789738-04-0
1789738-04-0 structure
- Name: AMY-101 TFA
- Chemical Name: AMY-101 TFA
- CAS Number: 1789738-04-0
- Molecular Formula: C83H117N23O18S2.xC2HF3O2
- Molecular Weight:
- Catalog: Signaling Pathways Anti-infection SARS-CoV
- Create Date: 2020-06-01 12:41:12
- Modify Date: 2024-01-02 18:51:23
-
AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2].
| Name | AMY-101 TFA |
|---|
| Description | AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2]. |
|---|---|
| Related Catalog | |
| Target |
KD: 0.5 nM (C3)[1]. |
| In Vivo | AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis[1]. AMY-101 can induce a long-lasting anti-inflammatory effect[1]. AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction[1]. Animal Model: Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7 – 15 years old; 5.0 – 7.6 kg body weight)[1]. Dosage: 0.1 mg/site; 50 μL of 2 mg/mL solution. Administration: Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.) Result: Does not cause irritation in healthy gingiva. |
| References |
| Molecular Formula | C83H117N23O18S2.xC2HF3O2 |
|---|